The DOI matches its Crossref record; 131 of the 149 references it cites were found in a registry or an index, and 5 are not checked yet.
Accelerated COVID-19 vaccine development: milestones, lessons, and prospects
Open accessAbstract
The development of effective vaccines to combat infectious diseases is a complex multi-year and multi-stakeholder process. To accelerate the development of vaccines for coronavirus disease 2019 (COVID-19), a novel pathogen emerging in late 2019 and spreading globally by early 2020, the United States government (USG) mounted an operation bridging public and private sector expertise and infrastructure. The success of the endeavor can be seen in the rapid advanced development of multiple vaccine candidates, with several demonstrating efficacy and now being administered around the globe. Here, we review the milestones enabling the USG-led effort, the methods utilized, and ensuing outcomes. We discuss the current status of COVID-19 vaccine development and provide a perspective for how partnership and preparedness can be better utilized in response to future public-health pandemic emergencies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“mRNA vaccines are promising alternatives to conventional vaccines because of their high potency, low manufacturing cost, and short preparation period (Bok et al., 2021; Chaudhary et al., 2021).”
From A novel Toxoplasma gondii TGGT1_316290 mRNA-LNP vaccine elicits protective immune response against toxoplasmosis in mice (2023) · cites this paper as Bok et al., 2021
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Vahidy, F., Pischel, L., Tano, M., Pan, A. P., Boom, M. L., Sostman, H. D., Nasir, K., & Omer, S. B. (2021) · medRxiv · doi:10.1101/2021.04.21.21255873 · Cited by 18
RetractedSafety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592 · cited 2×
“Pfizer/BioNTech conducted their phase 3 efficacy trial in 150 sites around the world, including those in the United States, Argentina, Brazil, South Africa, Germany, and Turkey (Pfizer, 2020a, 2020b; Polack et al., 2020).”
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S. A., Rouphael, N., Creech, C. B., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2035389 · Cited by 10,119
Self-citationCryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Self-citationFirst case of 2019 novel coronavirus in the United States
Holshue, M. L., DeBolt, C., Lindquist, S., Lofy, K. H., Wiesman, J., Bruce, H., Spitters, C., Ericson, K., Wilkerson, S., Tural, A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001191 · Cited by 6,030
Pushko, P., Pumpens, P., & Grens, E. (2013) · Intervirology · doi:10.1159/000346773 · Cited by 5,975
mRNA vaccines — a new era in vaccinology
Pardi, N., Hogan, M. J., Porter, F. W., & Weissman, D. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.243 · Cited by 4,667
An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., McCullough, M. P., Chappell, J. D., Denison, M. R., Stevens, L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022483 · Cited by 3,237
Self-citationEffectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant
Lopez Bernal, J., Andrews, N., Gower, C., Gallagher, E., Simmons, R., Thelwall, S., Stowe, J., Tessier, E., Groves, N., Dabrera, G., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2108891 · Cited by 2,889
Effectiveness of COVID-19 vaccines against the B.1.617.2 variant
Bernal, J. L., Andrews, N., Gower, C., Gallagher, E., Simmons, R., Thelwall, S., Stowe, J., Tessier, E., Groves, N., Dabrera, G., et al. (2021) · doi:10.1101/2021.05.22.21257658 · Cited by 2,888 · cited 2×
“While most immunocompromised individuals were ineligible for the phase 3 efficacy Sponsor Real-world vaccine effectiveness against prototype SARSCoV-2 strain Real-world vaccine effectiveness against SARS-CoV-2 variants Alpha (B.1.1.7) Beta (B.1.351) Gamma (P.1) Delta (B.1.617.2) I/SI SD I/SI SD I/SI SD I/SI SD Pfizer/…”
BackgroundInfluential
Flagged first, then by citations
13 of the 149 references couldn’t be matched to a known paper.
Research works printed but not linked: 5
- Andrejko, 2021, Early evidence of COVID-19 vaccine effectiveness within the general population of California, medRxiv
- Barouch, 2021, Durable Humoral and Cellular Immune Responses Following Ad26.COV2.S Vaccination for COVID-19, medRxiv
- Swift, 2021, Effectiveness of mRNA COVID-19 vaccines against SARS-CoV-2 infection in a cohort of healthcare personnel, Clin. Infect. Dis.
- Tande, 2021, Impact of the COVID-19 Vaccine on Asymptomatic Infection Among Patients Undergoing Pre-Procedural COVID-19 Molecular Screening, Clin. Infect. Dis.
- Walsh, 2020, Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates, N. Engl. J. Med., 383, 2439, 10.1056/NEJMoa2027906 · DOI · Paper page
Cited by
Sorted by citations
Items 201–254 of 254
Controversies about COVID-19 vaccines and vaccination in the journalistic media
Gonçalves, B. A., Itagyba, R. F., Matos, C. C. D. S. A., & Couto, M. T. (2025) · Ciência & Saúde Coletiva · doi:10.1590/1413-81232025305.14472023en · Cited by 1
One year of COVID-19 vaccination
Cheng, M., Zhao, H. J., & Qin, C. (2022) · National Science Open · doi:10.1360/nso/20220007 · Cited by 1
Comparison of Axillary Lymph Nodes on Breast MRI Before and After COVID-19 Booster Vaccination
Parikh, R., Feigin, K., Sevilimedu, V., Huayanay, J., Pinker, K., & Horvat, J. V. (2023) · Academic Radiology · doi:10.1016/j.acra.2023.03.012 · Cited by 1
Takagi, A., & Matsui, M. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.09.21.461322 · Cited by 1
Determinants of COVID-19 Vaccine Acceptability in Mozambique: The Role of Institutional TrustPreprint
Hu, B., Yang, W. Y. L., Bouanchaud, P., Chongo, Y., Wheeler, J., Chicumbe, S., & Chissano, M. (2022) · medRxiv · doi:10.1101/2022.03.03.22271828 · Cited by 1
Large-scale deployment of SIT-based technology in a Brazilian city prevented Dengue outbreakPreprint
Poncio, L. D. C., dos Anjos, F. A., de Oliveira, D. A., da Rosa, A. D. O., Silva, B. P., Rebechi, D., Franciscato, D. A. D. C., de Souza, C., Paiva, U., Mazurechen, M., et al. (2022) · medRxiv · doi:10.1101/2022.09.19.22279924 · Cited by 1
Sengupta, A., Al-Otaibi, N., Devito, C., Lottersberger, F., & Hinkula, J. (2022) · Research Square · doi:10.21203/rs.3.rs-2210670/v1 · Cited by 1
One year of COVID-19 vaccination
Cheng, M., Zhao, H. J., & Qin, C. (2022) · National Science Open · doi:10.1051/nso/2022003
Liu, H., Wu, L., Liu, B., Xu, K., Lei, W., Deng, J., Du, P., Han, P., Wang, L., Wang, D., et al. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4001946
Technology and Innovation for Societal Resilience Through Multistakeholder Collaboration
Pramanik, R. (2022) · Disaster risk reduction · doi:10.1007/978-981-19-2053-0_14
Li, L., Guo, P., Yang, Y., Dai, J., Gu, F., Lan, X., Tang, X., & Yu, H. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4195242
The Silver Lining of the COVID-19 Pandemic: Fast-Tracked Vaccine Production and Approval
Mandala, W. L. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.107254 · Cited by 1
Sengupta, A., Al-Otaibi, N., Devito, C., Lottersberger, F., & Hinkula, J. (2022) · Research Square · doi:10.21203/rs.3.rs-2037306/v1
Local monitoring of SARS-CoV-2 variants in two large California counties in 2021
Kojima, N., Khorosheva, E. M., Lopez, L., Hanewich-Hollatz, M. H., Ignacio‐Espinoza, J. C., Brobeck, M., Chen, J., Geluz, M. I., Hess, V., Quasem, S., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-21481-0
Anwith, H. S., Mariyam, D., Madhusudan, M., Ramegowda, C., & Hulugappa, L. (2022) · Apollo Medicine · doi:10.4103/am.am_92_22
Clar, M., Walker, A., & Solomon, P. (2023) · Springer eBooks · doi:10.1007/978-3-030-01782-8_126-1
The Next Pandemic: Challenges and Hopes
Ferreira, C., Doursout, M.-F. J., & Balingit, J. S. (2023) · Springer eBooks · doi:10.1007/978-3-031-10035-2_15
Jiménez, M., Ríos, H., Gómez, P., Tavera, M. E., Gómez, R. J. S., Pérez, F., Martínez, M. D. L. Á., García, I. L., Romero, J. A., Piedra, N. R. A., et al. (2022) · International Journal of Vaccines & Vaccination · doi:10.15406/ijvv.2022.07.00112
Arrúa, W. J., Kennedy, M. L., & Galeano, A. K. (2023) · Revista de la Sociedad Científica del Paraguay · doi:10.32480/rscp.2023.28.1.71
Hwang, J. W., Chien, S. J., Wang, C., Kuo, K.-C., Tang, K.-S., Lee, Y., Chen, Y., Lo, M., Lee, I., Chuah, S., et al. (2023) · Adolescent Health Medicine and Therapeutics · doi:10.2147/ahmt.s429238
Self-replicating RNA viruses in vaccine development
Lundstrom, K. H. (2023) · Exploration of Medicine · doi:10.37349/emed.2023.00168
Nanoscale Vaccines for the Prevention of COVID-19
Iqbal, M. J., Hamdani, T., Attarwala, H. Z., & Amiji, M. M. (2023) · AAPS advances in the pharmaceutical sciences series · doi:10.1007/978-3-031-39020-3_13
Aldana-Vásquez, B., González-Labadie, G., Herrera-González, I., Jorquera, V. L., Ramos-Berenguer, M., & López-Alegría, F. (2023) · Revista chilena de obstetricia y ginecología · doi:10.24875/rechog.23000049
Alanazi, A. S. (2023) · Journal of Medicine and Health Studies · doi:10.37881/jmahs.223
Modelling the Dynamics of Multi-strain COVID-19 Transmission
Ndam, J. N., & Agba, S. T. (2023) · Open Journal of Mathematical Sciences · doi:10.30538/oms2023.0210
Sengupta, A., Al-Otaibi, N., Devito, C., Lottersberger, F., & Hinkula, J. (2024) · Vaccines · doi:10.3390/vaccines12030320
The Future of HIV Vaccine Development, Learned Lessons from COVID-19 Pandemic
Mohamed, Y. I. (2024) · Pharmaceutical science. · doi:10.5772/intechopen.114355
Uma estratégia de vacinação Envy-free
Almeida, P. R. (2024) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.43.2024.tde-28022024-082900
Gasmi, A., Semenova, Y. M., Noor, S., Nehaoua, A., Malek, R., Malek, H., & Bjørklund, G. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95648-2.00005-8
Yang, J. E., Fan, H., Yang, A., Wang, W., Wan, X. H., Lin, F., Yang, D., Wu, J., Wang, K., Li, W., et al. (2024) · Vaccines · doi:10.3390/vaccines12070742
Yazdanpanah, Y., Madelaine, C., Pulik, N., & Souteyrand, Y. (2024) · Springer eBooks · doi:10.1007/978-3-031-48408-7_43
12.1 In Focus: Novel Manufacturing Platforms for Pandemic Preparedness and Emergency Response
Bok, K. (2024) · Springer eBooks · doi:10.1007/978-3-031-48408-7_15
Self-citation12 Vaccine Candidates for Novel Pathogens
Bok, K. (2024) · Springer eBooks · doi:10.1007/978-3-031-48408-7_14
Self-citationInfectious diseases and global security: Analysis of global control and vaccination strategies
Strzelecka, B., Neçaj, L., Wisniewska, K., Stróż, S., & Bartoszewicz, M. (2024) · Salud Ciencia y Tecnología · doi:10.56294/saludcyt2024.582
Predictors of COVID-19 Vaccine Hesitancy in North-Central Nigeria
Olutola, A., Gobir, I. B., Bazira, D., Agboola, S., Sanni, F. O., Bello, A. A., Havila, N. O., Adamu, A., Bello, F., Otubo, S. A., et al. (2024) · Journal of Immunization · doi:10.14302/issn.2577-137x.ji-24-5207
Forero-Peña, D. A., Leyva, J. L., Valenzuela, M. V., Omaña‐Ávila, Ó. D., Regalado-Gutiérrez, O. A., Mendoza-Millán, D. L., Sánchez-Ytriago, E. A., Hachem, A. C. L.-E., Farro, K. R., Maita, A. K., et al. (2024) · Discover Public Health · doi:10.1186/s12982-024-00259-x
A paradoxical view of speed and quality in firms’ operations
Guo, F., Tong, X., & Zhang, X. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-28993-4.00091-3
Nanotherapeutics in COVID-19 and associated pulmonary infections
Mir, Z. M., Thakur, P., Arora, R., Kanwar, N., & Baldi, A. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-28836-4.00016-0 · Cited by 1
Bushi, G., Gaidhane, A. M., Vadia, N., Menon, S. V., Chennakesavulu, K., Panigrahi, R., Shabil, M., Jena, D., Kumar, H., Rani, A., et al. (2025) · Health Science Reports · doi:10.1002/hsr2.70882
Etuk, V., Omonijo, O., Sanni, C., Atema, S., Abimiku, A., & Okpokoro, E. (2025) · medRxiv · doi:10.64898/2025.12.05.25341692
COVID-19 Vaccination and Lethality Reduction: A Prospective Cohort Study in VenezuelaPreprint
Forero-Peña, D. A., Leyva, J. L., Valenzuela, M. V., Omaña-Ávila, Ó. D., Mendoza-Millán, D. L., Sánchez-Ytriago, E. A., Hachem, A. C. L.-E., Farro, K. R., Maita, A. K., González, R. D. C., et al. (2024) · Research Square · doi:10.21203/rs.3.rs-3813947/v1
COVID-19 Vaccination and Mortality Reduction: A Prospective Cohort Study in VenezuelaPreprint
Forero-Peña, D. A., Leyva, J. L., Valenzuela, M. V., Omaña-Ávila, Ó. D., Mendoza-Millán, D. L., Sánchez-Ytriago, E. A., Hachem, A. C. L.-E., Farro, K. R., Maita, A. K., González, R. D. C., et al. (2023) · Research Square · doi:10.21203/rs.3.rs-3396851/v1
Vizuet, A. L. V., Aguilar-Muñoz, E., & Lobato-Tapia, C. A. (2025) · Journal of Herbal Medicine · doi:10.1016/j.hermed.2025.101085
Ghosh, M. K. (2025) · Medical virology · doi:10.1007/978-981-95-1426-7_1
Park, S., Mischka, J., Okba, N. M. A., Abbad, A., Yuan, M., Srivastava, K., Gleason, C., Mulder, L. C. F., Copps, J., Saam, K., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.02.18.706653 · Cited by 1
Hudson, A., Borgetti, S. A., Rick, A.-M., Laurens, M. B., Robinson, S. T., Gay, C. L., Baden, L. R., Goepfert, P., Rouphael, N., Sahly, H. M. E., et al. (2026) · Vaccine · doi:10.1016/j.vaccine.2026.128380
Harnessing Herbal Wisdom against SARS-CoV-2: A Review of Plant-derived Antiviral Agents
Sumaiya, Saini, H., Panwar, G., ., P., Bahukhandi, S., Gaur, U., Kumar, R., Panti, S., Kumar, A. A., & Karn, S. K. (2026) · Journal of Natural Remedies · doi:10.18311/jnr/2026/52063
Boulet, S., Thevenet, V., Abécassis, J., Collignon, C., Giraudeau, B., Lhomme, E., Petit, F., Porcher, R., Richert, L., Saillour, F., et al. (2026) · BMJ Digital Health & AI · doi:10.1136/bmjdh-2026-000043
Acacetin-incorporated lipid nanoparticles for inhaled mRNA vaccines
Huang, X., Fan, K., Zhang, Y., Yang, Y., Wang, Y., Yang, X., Meng, Z., Guo, Q., Li, Y., Gong, N., et al. (2026) · Nanoscale Horizons · doi:10.1039/d5nh00794a
Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2)
Modjarrad, K., & Swanson, K. A. (2026) · Springer eBooks · doi:10.1007/978-3-032-37993-1_12
BindingDB (2024) · UC San Diego · doi:10.7270/q2xg9wg8
Metadata
- Authors
- Bok, K., Sitar, S., Graham, B. S., & Mascola, J. R.
- Affiliations
- National Institutes of Health (US)
- Corresponding author
- Mascola, John R.
- Venue
- Immunity
- Publisher
- Elsevier BV
- Published
- 2021-08
- Volume
- 54
- Issue
- 8
- Pages
- 1636-1651
- ISSN
- 1074-7613 (ISSN-L)
- PMC
- PMC8328682
- OpenAlex
- W3187496430
- Cited by
- 254
- References
- 149
- Citations by year
- 2026: 9 · 2025: 36 · 2024: 46 · 2023: 74 · 2022: 77 · 2021: 12
- FWCI
- 6.11
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Immunity (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- U.S. Department of Health and Human Services (63/140,250, PCT/US2021/017709, WO/2018/081318)
- Centers for Disease Control and Prevention
- National Institute of Allergy and Infectious Diseases
- Biomedical Advanced Research and Development Authority
- National Institutes of Health
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Legal, Health, Environmental and COVID-19 Challenges
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- COVID-19 vaccine development, SARS-CoV-2, public-private partnerships, vaccine candidate, pandemic preparedness, public health emergencies, vaccine efficacy
- MeSH terms
- Vaccination Coverage, Vaccinology, COVID-19, SARS-CoV-2, COVID-19 Vaccines, Biotechnology, Humans, Models, Molecular, Research, United States, Outcome Assessment, Health Care, Bioengineering, Public Health Surveillance
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
